Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 3,499 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,499 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the completion of the transaction, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.04, for a total transaction of $16,699.48.
• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $68,256.24.

Nurix Therapeutics Trading Down 2.7 %

NRIX stock traded down $0.35 during mid-day trading on Thursday, reaching $12.73. 1,200,167 shares of the stock traded hands, compared to its average volume of 949,614. The company has a market cap of $625.68 million, a P/E ratio of -4.88 and a beta of 2.10. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $18.12. The stock’s fifty day moving average is $13.76 and its 200-day moving average is $9.86.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The firm had revenue of $15.16 million for the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. Equities research analysts expect that Nurix Therapeutics, Inc. will post -3.15 earnings per share for the current year.

Analyst Ratings Changes

NRIX has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Royal Bank of Canada raised their price objective on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, February 16th. Finally, HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NRIX. China Universal Asset Management Co. Ltd. boosted its position in Nurix Therapeutics by 351.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after acquiring an additional 4,367 shares during the period. Quest Partners LLC purchased a new stake in shares of Nurix Therapeutics in the fourth quarter worth approximately $59,000. Principal Financial Group Inc. boosted its holdings in shares of Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock worth $122,000 after purchasing an additional 2,002 shares during the period. Jump Financial LLC acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth approximately $158,000. Finally, SG Americas Securities LLC purchased a new position in Nurix Therapeutics during the third quarter valued at approximately $162,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.